Endocrine Abstracts

Introduction: Type 5 phosphodiesterase (PDE5) inhibitors (PDE5i) lead to intracellular cyclic-guanosine monophosphate (cGMP) increase and are used for clinical treatment of erectile dysfunction. Studies found that cGMP may up/downregulate the growth of certain endocrine tumor cells, suggesting that the use of PDE5i could impact the risk of certain tumors, such as colorectal cancer.Aim: We evaluated if PDE5i may impact thyroid cancer cell growth in vi...